Spotlighting Shifting Treatment Trends in Acute Lymphoblastic Leukemia

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab in acute lymphoblastic leukemia management.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab consolidation in BCR:ABL1–negative B-ALL.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss data for subcutaneous in relapsed/refractory acute lymphoblastic leukemia.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.